Compare Amphastar Pharmaceuticals Inc (AMPH) vs Diageo plc (DEO) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Diageo (DEO) trades at $82.03, up 1.76% with bearish technical signals but mixed fundamentals. The stock shows strong profitability with 12.19% net margins and 22.29% ROE, though recent earnings were mixed with a Q2 2025 miss. Analyst sentiment leans positive with 49% buy ratings, but technical indicators show 15 sell signals versus 1 buy. Recent news highlights CEO Dave Lewis's upcoming strategy update amid US market challenges and promotional increases to stabilize sales.

The outlook remains cautious due to weak US demand and competitive pressures, but valuation at multi-year lows and cost-saving initiatives offer potential upside. Key risks include execution on the new strategy and consumer spending trends. Investors should weigh the dividend yield and recovery potential against near-term headwinds.